Tweets
"Don’t ever let anyone tell you you ain’t strong enough" – Janis Joplin https://t.co/1B1YD5gDLk
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago
Uveitis Risk with Slow Adalimumab Weaning
Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/KgQsK6fVnr
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago
2nd Opinions in Rheumatology
https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago
Vamorolone: a New Steroid on the Horizon?
Vamorolone is a potentially new alternative to traditional glucocorticoids for use in inflammatory diseases. It is a dissociated steroidal compound with reduced side effects, and in an animal model of inflammation has shown effective https://t.co/38WTOAuuJy
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago
Summary of the updated BSR Axial Spondyloarthritis for biological and targeted synthetic DMARD guidelines 2025 @RheumatologyUK #axialspondyloarthritis
Full paper available at:
https://t.co/LytDiHjawi https://t.co/iaHzD1BQRe
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
9 months 2 weeks ago
📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF
Links:
BSR @RheumatologyUK ( View Tweet )
9 months 2 weeks ago
Prof Ian Giles will be covering a range of topics at this year's Rheumapreg Conference such as how immunologic changes and placental dysfunction cause adverse outcomes in rheumatic disease pregnancies.
View the full prgramme and learn more: https://t.co/tjiycjKJ8i https://t.co/FugHvtm8fY
BSR @RheumatologyUK ( View Tweet )
9 months 2 weeks ago
In our latest episode, @deodhara takes us behind the scenes of his research on IV secukinumab in #AxSpA. Discover key findings from the INVIGORATE-1 study, how it’s shaping treatment options, & what’s next in AxSpA research. LISTEN NOW → https://t.co/2IBixQSdpO @ACR_Journals https://t.co/HzcJw0pzWI
Links:
American College of Rheumatology @ACRheum ( View Tweet )
9 months 2 weeks ago
43 days to the Lupus Congress 2025 in Toronto 🦋...see you soon!
Abstract Sessions, Poster Tour Presentations, Plenary Sessions, Scientific Sessions, Debate Sessions, Patient Sessions, Fishbowl Discussion, and GALA DINNER on May 23!!!
@LupusCongress https://t.co/MaWjyofnIz
Zahi Touma, MD, PhD @ZahiTouma ( View Tweet )
9 months 2 weeks ago
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Sponsored by UCB
https://t.co/461bFRZwjw
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago
Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including:
nipocalimab
VAY736 (ianalumab)
HZN-1116
AMG 329
R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG
Links:
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago
Patient info on Sweets Syndrome: acute febrile neutrophilic dermatosis
https://t.co/0q93q2NVc9 https://t.co/cE3LA8LaRQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
9 months 2 weeks ago


